Should I have disease-modifying therapy for multiple sclerosis?

References

Citations

1. National Clinical Advisory Board of the National Multiple Sclerosis Society (2007). Disease Management Consensus Statement. New York: National Multiple Sclerosis Society. Available online: http://www.nationalmssociety.org/site/PageServer?pagename=HOM_PRO_expert_opinion_papers.

2. Sadiq SA (2005). Multiple sclerosis. In LP Rowland, ed., Merritt's Neurology, 11th ed., pp. 941–963. Philadelphia: Lippincott Williams and Wilkins.

3. Nicholas R, Chataway J (2006). Multiple sclerosis, search date January 2006. Online version of BMJ Clinical Evidence. Also available online: http://www.clinicalevidence.com.

4. Polman CH, et al. (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine, 354(9): 899–910.

5. Rudick RA, et al. (2006). Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine, 354(9): 911–923.

Author:	Monica Rhodes	Last Updated: February 28, 2008
Medical Review:	Anne C. Poinier, MD - Internal Medicine Colin Chalk, MD, CM, FRCPC - Neurology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.